CN Menu
About us
about Evergreen
Focus on Unmet Clinical Needs and Achieve Medical Value

Established in August 2019 in Shenzhen, China, Evergreen Therapeutics is an international, innovative, clinical-stage pharmaceutical company. It is committed to meeting the clinical needs and achieving medical value to benefit patients worldwide. Headquartered in Shenzhen, Evergreen has office and laboratory in the United States. Established for more than two years, Evergreen has developed rapidly and has become a leader in efficient R&D of Chinese innovative pharmaceutical enterprise and a pioneer in internationalization of Chinese innovative pharmaceutical enterprise.


Evergreen applies artificial intelligence (AI) and has always adhered to a global and differentiated development strategy, focusing on the research and development of innovative drugs in the fields of autoimmunity, ophthalmology, chronic diseases, etc. While exploring new targets, the company also actively develops new indications for existing drugs. At present, Evergreen has 80 patent licenses and 13 product pipelines, and has been granted for 15 patents. Four of which have entered clinical stage. The patents cover major global pharmaceutical markets including China, United States, Europe, Japan, and others; product pipelines include a broad range of drugs, including treatment for COVID-19, idiopathic interstitial pneumonia, and endometrial cancer.

13
+
13 Product Pipelines
80
+
80 Patents Licensing
4
+
4 Clinical Drug Candidates
Values
Continuously explore clinical needs and realize medical value through strong R&D and innovation
Mission
Focus On Unmet Clinical Needs and Achieve Medical Value
Vision
To become the most dynamic and innovative pharmaceutical company in China
DEVELOPMENT HISTORY
2019
08-26:
Evergreen Therapeutics Inc. was formally established
09-05:
Cooperate with McGill University in the research and development of respiratory drugs
2020
01-01:
Dr. Du Xin joined Evergreen Therapeutics Inc. as CEO
09-23:
EG-009 was officially approved by the FDA for phase I clinical trials
10-13:
EG-001 was officially approved by the FDA for phase I clinical trials
10-27:
EG-009A was officially approved by the FDA for phase II clinical trials
12-10:
Phase I clinical trials launched: an oral treatment for COVID-19
2021
03-15:
Raised RMB 100 million in Series A financing to develop Covid-19 clinical drugs
07-01:
Third Quarter - EG009A was officially in Phase II clinical trials
07-19:
Dr. Charles Lee joined Evergreen Therapeutics as Chief Medical Officer
08-11:
The U.S. Food and Drug Administration (FDA) has approved the entry of Eg-007 into a pivotal phase III clinical trial
09-14:
COVID-19 Drug EG-009A has been approved for phase II clinical trials in India
2022
2019
08-26:
Evergreen Therapeutics Inc. was formally established
09-05:
Cooperate with McGill University in the research and development of respiratory drugs
2020
01-01:
Dr. Du Xin joined Evergreen Therapeutics Inc. as CEO
09-23:
EG-009 was officially approved by the FDA for phase I clinical trials
10-13:
EG-001 was officially approved by the FDA for phase I clinical trials
10-27:
EG-009A was officially approved by the FDA for phase II clinical trials
12-10:
Phase I clinical trials launched: an oral treatment for COVID-19
2021
03-15:
Raised RMB 100 million in Series A financing to develop Covid-19 clinical drugs
07-01:
Third Quarter - EG009A was officially in Phase II clinical trials
07-19:
Dr. Charles Lee joined Evergreen Therapeutics as Chief Medical Officer
08-11:
The U.S. Food and Drug Administration (FDA) has approved the entry of Eg-007 into a pivotal phase III clinical trial
09-14:
COVID-19 Drug EG-009A has been approved for phase II clinical trials in India
2022
Management Team
Tom Du, M.D., Ph.D.
Chairman
Chairman
Tom Du, M.D., Ph.D.
He graduated from Tianjin Medical University and received his PhD from McGill University in Canada. He received two years of post-doctoral training at Harvard University in the United States, under professor Frank Austen, member of the National Academy of Sciences. Since 1994, he has served as a new drug reviewer for FDA for 7 years. After joining FDA in late 2000, he served as the Director of The Registration Division of United Healthcare Corporation in the United States and senior Director of Clinical and Registration Division of Hutchison Whampoa Pharmaceuticals in Hong Kong. Since then, he has served as Humphrey's chief pharmaceutical development consultant in Humphrey Medical Consulting Co., LTD., leading a new drug development team from different countries, different cultural backgrounds and different specialties to successfully complete more than 100 new drug development and application work. He is currently a visiting professor of Peking Union Medical College, president of FDA Society and president of the Association of Regulations and Agreements.
View More
The Team Has Strong Independent Research And Development Capabilities
David Du, Ph.D
CEO
CEO
David Du, Ph.D
He received his PhD in Biochemistry, University of Florida in the USA. He also did postdoctoral research at the National College of Medicine in the United States. Former FDA review officer, senior executives of many large and medium-sized international pharmaceutical companies, experts familiar with the entire process of FDA and global drug development, manufacturing, quality management, clinical design, drug product marketing application, and global post-marketing management of drug products. Dr. Du used to be a CMC reviewer of FDA, responsible for IND and BLA review of biological drugs. Subsequently, he worked at Aventis-Pastuer/Sanofi, Wyeth/Pfizer, Novartis, BMS, NPS and other multinational pharmaceutical companies. In the pharmaceutical industry more than 20 years of work, prevent new doctor for four biological medicine licenses approved by FDA, two biological drug approvals in the European Union and Canada, and countless IND in the United States, China, Europe, and other state approval, related to the size of the molecules, cells and genes, soluble tumor virus and medical devices and other various types of products. He has experience in managing medicines marketed in more than 30 countries.
View More
Charles Lee, M.D, Ph.D
CMO
CMO
Charles Lee, M.D, Ph.D
He graduated from Xi 'an Jiaotong University School of Medicine and received his Master's degree in hospital Administration and doctor of Public Health degree from the University of Alabama Birmingham, USA. He did three years of residency at the University of Chicago Medical Center and obtained the American Physician license and the American Clinical Pathology Specialist certification. He used to be a senior medical reviewer of THE US Food and Drug Administration (FDA), and was the first overseas Chinese to enter FDA's clinical review as a doctor. Dr. Changqing Li has extensive experience in phase I-IV global clinical trials in oncology, immunotherapy, anti-inflammatory, gastrointestinal diseases, and gynecological diseases. He has led hundreds of clinical trials and more than 30 new drug filings worldwide, developing overall solutions for global drug development, regulatory registration, clinical strategy and risk management.
View More
Tao Hu, Ph.D
Director of Pharmacology
Director of Pharmacology
Tao Hu, Ph.D
Bachelor of Pharmacy, Master of Pharmacology, Peking University Health Science Center; Doctor of Biomedical Science, Chinese University of Hong Kong. Postdoctoral fellow, School of Pharmacy, University of Washington, 2015-2018. Scientist, Clinical Pharmacology Division, FDA, 2018-2020. He has published more than 20 research papers in the fields of pharmacology, pharmacokinetics and drug interactions, and participated in editing and writing 2 academic papers. He has rich experience in pharmacological experiment design and drug mechanism research.
View More
Yuqian Zhang, Ph.D
Director of Immunology
Director of Immunology
Yuqian Zhang, Ph.D
PhD of biochemistry at University of Kentucky; postdoctoral fellow at Johns Hopkins University and University of California, Los Angeles; associate researcher at Chinese Academy of Medical Sciences; worked on R&D related to immunotherapy in many research institutions and pharmaceutical companies in China and the U.S.
View More
Shanshan Li, Ph.D
Director of CMC
Director of CMC
Shanshan Li, Ph.D
Bachelor of Chemistry, Tsinghua University; Doctor of Pharmacy, Rutgers University, New Jersey, USA; With nearly 10 years of CMC working experience in the pharmaceutical industry, I am proficient in leading the whole industry chain process of topic selection and project approval, formula research and development, scale-up production, FDA application, commercial batch production and listing of products.
View More
Paolo Baroldi, M.D., Ph.D
SVP, Clinical Affairs
SVP, Clinical Affairs
Paolo Baroldi, M.D., Ph.D
PhD in Clinical Pharmacology, Diploma from Harvard Business School Executive Education. An outstanding physician and clinical pharmacologist with more than 35 years of experience in pharmaceutical industry and drug development led the R&D of 25 new drugs including epirubicine, imatinib. Expertise in a wide variety of therapeutic areas.
View More
Patrick McGrath, Ph.D
VP, Clinical Operation
VP, Clinical Operation
Patrick McGrath, Ph.D
PhD at University of Missouri, rich experience in clinical design, operation, and regulations in multiple therapeutic areas, professional knowledge of prescription drugs regulations in the U. S., is responsible for implementing the company's clinical trials.
View More
Minghan Cui
BD Associate Director
BD Associate Director
Minghan Cui
Master of Pharmaceutical Engineering, South China Agricultural University; Used to be the marketing manager of clinical Coordination Department of Hengrui Pharmaceutical. Pfizer China Cardiovascular Group SMICS; Researcher of Pharmaceutical Research Institute of Guangyao Baiyunshan Pharmaceutical General Factory.
View More
SCIENTIFIC ADVISORY COMMITEE
Richard Moore, M.D. Clinical Development Consultant in Oncology
Dr. Moore is the Chair of Department of Gynecologic Oncology at the University of Rochester Medical Center. Former chair of the Department of Gynecologic Oncology at Brown University. He is an internationally recognized expert who uses biomarkers to detect ovarian cancer. Dr. Moore has a strong professional relationship with Evergreen and currently serves as the clinical development consultant in oncology.
View More
James Martin, M.D.Clinical Development Consultant in Basic Science and Respiratory Diseases
Dr. Martin is a renowned respiratory specialist, former chief of internal medicine at McGill University, former director of the Respiratory Disease Institute, and a leading expert in asthma and COPD, especially in asthma pathophysiology research. Currently he serves as a consultant of Evergreen on basic science and clinical trials of respiratory diseases.
View More
Florence Houn, M.D. Clinical Development Consultant of Anticancer and Other Drugs
Dr. Houn is a former outstanding leader of FDA, having served as the Office Director of CDER, CBER, and CDRH for 15 years. She also served as executive in MNCs, and is a former professor at Johns Hopkins University and an oncologist. Dr. Houn is currently a clinical development consultant of anticancer and other drugs in Evergreen.
View More
Robert Malone, M.D. Clinical Development Consultant of COVID-19 Drugs
Dr. Malone is renowned infectious disease expert. He received M.D. degree in Northwestern University, was postdoctoral fellow at Harvard University. He has more than 20 years of experience in clinical development of new drugs and participated in the design and supervision of about 40 clinical trials from Phase I to Phase III. Currently he is serving as a consultant of Evergreen on novel Coronavirus treatment drug development.
View More
About EvergreenABOUT EVERGREEN

Established in August 2019 in Shenzhen, China, Evergreen Therapeutics is an international, innovative, clinical-stage pharmaceutical company. It is committed to meeting the clinical needs and achieving medical value to benefit patients worldwide. Headquartered in Shenzhen, Evergreen has office and laboratory in the United States. Established for more than two years, Evergreen has developed rapidly and has become a leader in efficient R&D of Chinese innovative pharmaceutical enterprise and a pioneer in internationalization of Chinese innovative pharmaceutical enterprise.


Evergreen applies artificial intelligence (AI) and has always adhered to a global and differentiated development strategy,  focusing on the research and development of innovative drugs in the fields of autoimmunity, tumor immunity, chronic diseases, ophthalmology, etc. While exploring new targets, the company also actively develops new indications for existing drugs. At present, the company has 80 authorized patents and 13 product pipelines, and has been granted for 15 patents. Four drugs have entered clinical stage. The patents cover major global pharmaceutical markets such as China, theUnited States, Europe, and Japan. Several drugs are in the pipeline, ranging from treatment or COVID-19, toasthma, idiopathic interstitial pneumonia, and pediatric kidney disease; the market for these drugs looks promising.


Evergreen was founded by highly experienced pharmaceutical executives. Nearly all of senior management and R&D team members have experiences in the US FDA or at top international pharmaceutical companies. The advisory team also consists of world's top experts. While the company is constantly improving its internal research and development capabilities, the management team is also actively planning and hosting highly recognized,international medical conferences to discuss and promote new drug development and innovation in the pharmaceutical industry. 

With dual headquarters in Shenzhen, China, and Maryland, USA, Evergreen actively engages in international exchanges and investor communication while taking advantage of its location in the Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone.